TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Asher Biotherapeutics Stock

Asher Biotherapeutics Stock

asherbio.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $221.65MM

Asher Biotherapeutics, also known as Asher Bio, is a biotechnology company developing immunotherapies intended for cancer, autoimmune disorders, and infectious diseases. Asher Biotherapeutics was founded in 2019 by Ivana Djuretic and Andy Yeungand and is headquartered in San Francisco, CA. The company is committed to creating new treatment paradigms by using its proprietary cis-targeting platform to engineer therapies that selectively engage immune cells.

Buy or sell Asher Biotherapeutics stockLearn more about Asher Biotherapeutics IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Asher Biotherapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Asher Biotherapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Asher Biotherapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Asher Biotherapeutics investors also invested in these private companies

Wellington Management
Y Combinator
Emles Venture Partners
Ra Capital Management
Bristol Myers Squibb
Marshall Wace
Janus Henderson Investors
The Invus Group
Logos Capital
Third Rock Ventures
Boxer Capital
Alexandria Venture Investments
GoAhead Ventures
AstraZeneca
Mission BioCapital
MBC BioLabs

Team

Management Team

Andy Yeung Ph.D
Co-Founder & Chief Technology Officer
Ivana Djuretic Ph.D
Co-Founder & Chief Scientific Officer
Craig Gibbs Ph.D
Chief Executive Officer
Kyle Elrod
Chief Operating Officer
Don O'Sullivan Ph.D
Chief Business Officer

Board Members

Jeffrey Tong Ph.D
Third Rock Ventures
Reid Huber Ph.D
Third Rock Ventures
Robert Deresiewicz MD
Wellington Management

Frequently Asked Questions About Asher Biotherapeutics’ Stock

plusminus
Can you buy Asher Biotherapeutics’ stock?
Asher Biotherapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Asher Biotherapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Asher Biotherapeutics’ stock?
Yes, you can sell stock of a private company like Asher Biotherapeutics. Forge can help you sell your Asher Biotherapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Asher Biotherapeutics’ stock price?
Asher Biotherapeutics is a privately held company and therefore does not have a public stock price. However, you may access Asher Biotherapeutics’ private market stock price with Forge Data.
plusminus
What is Asher Biotherapeutics’ stock ticker symbol?
Asher Biotherapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Asher Biotherapeutics in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

FINSMES 04/17/2024
Asher Bio Closes $55M Series C Financing
In a funding round led by RA Capital Management, Asher Bio received $55 million to advance its lead clinical development program.

Trending Companies

Frequently Asked Questions

Updated on: Apr 23, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.